CARGO Therapeutics (CRGX)

Executive Summary

CARGO Therapeutics (NASDAQ: CRGX) is a clinical-stage biotechnology company developing next-generation CAR T-cell therapies to overcome resistance and relapse in cancer. Its lead candidate, CRG-022 (firi-cel), is a CD22-directed CAR T-cell therapy in Phase 2 for relapsed/refractory large B-cell lymphoma (LBCL) patients who have failed prior CD19-directed CAR T therapy. This addresses a critical unmet need, as approximately 50% of patients relapse after CD19 CAR T treatment. The company recently terminated a Phase 1/2 trial (NCT05972720) combining CRG-022 with lymphodepletion chemotherapy, but remains focused on advancing CRG-022 in a pivotal Phase 2 study. With a market capitalization of ~$210 million, CARGO represents a high-risk, high-reward opportunity in the competitive CAR T landscape. Key differentiators include its proprietary platform designed to enhance CAR T persistence and reduce exhaustion, potentially improving durability of responses. The company is well-capitalized to reach key milestones over the next 12-18 months.

Upcoming Catalysts (preview)

• Q4 2026Phase 2 data readout for CRG-022 in R/R LBCL35% success
• TBDPotential partnership or licensing deal for CRG-022 or platform technology20% success
• TBDInitiation of Phase 1 study for next-generation CAR T candidate25% success